Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Janssen-Cilag Pty Ltd |
---|---|
Information provided by: | Janssen-Cilag Pty Ltd |
ClinicalTrials.gov Identifier: | NCT00297271 |
The purpose of the PRIME (Prospective Research in Memory Clinics) Study is to examine the current management and outcomes of patients with dementia.
Approximately 4500 subjects will be enrolled in this disease registry across 12 sites in Australia. Clinical, treatment, health status and economic data will be acquired over 3 years. The study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes.
Condition |
---|
Dementia Alzheimer Disease |
Study Type: | Observational |
Official Title: | Prospective Research in MEmory Clinics (PRIME) |
Estimated Enrollment: | 4500 |
Study Start Date: | August 2005 |
The purpose of this study is to examine the current management of patients and outcomes of 4500 patients with dementia in Australia through a longitudinal (subjects are assessed at several different times during the course of the study), multiple cohort design (design containing group of individuals that share same characteristics) by collecting prospective real time clinical, treatment, health status and economic data. The study will identify the relationships among demographic variables, prognostic features(prediction of the probable course and outcome of a disease), geographic region, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes. A complete record of patient care will be collected to provide detailed information on the management and outcome of dementia and the profile of patients at participating sites. The data will be used to build models looking at the effect of dementia management on principal clinical events, health status and economic outcomes. This will provide the foundation for subsequent objective and prospective evaluation of strategies based on real-time data collected in this study for the optimal treatment of dementia in Australia. This study does not involve or require any treatment or medication by Sponsor, but will instead examine the influence of a whole range of routinely used treatment management strategies for dementia on clinical and economic outcomes among dementia patients in Australia. This 'practice based' approach is increasingly widely used and is a useful tool for elucidating the relative effectiveness of different management strategies and for exploring relationships between patient characteristics, treatment and outcomes.
NA - The registry will collect information irrespective of treatment prescribed.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: | info1@veritasmedicine.com |
Australia | |
Austin & Repatriation Medical Centre | Recruiting |
Heidelberg, Australia, 3084 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: MICHAEL WOODWARD | |
Prince Charles Hospital Health Service District Hrec | Recruiting |
Chermside N/A, Australia, 4032 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: CHRIS DAVIS | |
Prince of Wales Hospital | Active, not recruiting |
Randwick, Australia, 2031 | |
Fremantle Hospital | Recruiting |
Fremantle, Australia, 6160 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: ROGER CLARNETTE | |
Rankin Park Centre | Recruiting |
Newcastle, Australia, 2305 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: John Ward | |
Queen Elizabeth Hospital | Recruiting |
Woodville, Australia, 5011 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: KARYN BOUNDY | |
Geelong Private Hospital | Recruiting |
Geelong, Australia, 3220 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: Alistair Mander | |
Hornsby Ku-ring-gai | Recruiting |
Hornsby, Australia, 2077 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: SUSAN KURRLE | |
St George's Hospital | Recruiting |
Kew, Australia, 3101 | |
Contact: Rebecca Cargill +1 (612) 887-5334 | |
Principal Investigator: DAVID AMES |
Study Director: | Janssen-Cilag Pty Ltd Clinical Trial | Janssen-Cilag Pty Ltd |
Study ID Numbers: | CR004819 |
Study First Received: | February 24, 2006 |
Last Updated: | February 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00297271 History of Changes |
Health Authority: | Australia: Department of Health |
Dementia Patient Registries Cholinesterase Inhibitor costs and outcomes Alzheimer Disease |
Cholinesterase Inhibitors Neurotransmitter Agents Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases |
Cholinergic Agents Neurodegenerative Diseases Brain Diseases Dementia Cognition Disorders Delirium |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Alzheimer Disease Nervous System Diseases Central Nervous System Diseases Enzyme Inhibitors Cholinergic Agents |
Brain Diseases Neurodegenerative Diseases Pharmacologic Actions Cholinesterase Inhibitors Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Dementia Tauopathies |